Retatrutide, a novel dual-action GIP receptor stimulant developed by Alluvi Biopharma, is sparking considerable excitement within the healthcare community as a potential advancement in weight loss. Initial clinical data indicate a significant impact on body size, often outperforming current existing therapies. This distinctive mechanism of action,